Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer

Charlotte Fribbens(Institute of Cancer Research), Nicholas C. Turner(Royal Marsden NHS Foundation Trust), Michael Epstein(Granta Design (United Kingdom)), Ben O’Leary(Institute of Cancer Research), Sarah Hrebien(Breast Cancer Now), Lucy Kilburn(Institute of Cancer Research), Nitzan Rosenfeld(University of Cambridge), Matthew Beaney(Breast Cancer Now), Karen Howarth(Granta Design (United Kingdom)), E. Green(Granta Design (United Kingdom)), Alistair Ring(Brighton and Sussex Medical School), S. Johnston(Royal Marsden Hospital), Isaac García-Murillas(Breast Cancer Now)
Annals of Oncology
October 3, 2017
10.1093/annonc/mdx483
Cited by 158

Related Papers

Liquid biopsies come of age: towards implementation of circulating tumour DNA
|Nature reviews. Cancer|2017|2.6k
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
|New England Journal of Medicine|2015|1.6k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
|New England Journal of Medicine|2018|1.3k